Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.

28 Oct 2013

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Patients with severe rheumatoid arthritis more likely to have heart problems

People with rheumatoid arthritis and other chronic inflammatory conditions are at higher risk of heart disease. Who is in the most danger, why and how best to prevent and detect cardiovascular complications are important questions for physicians and researchers.

28 Oct 2013

Autoimmune link to schizophrenia

Patients with schizophrenia have an increased risk for developing autoimmune diseases, especially if they contract an infection, shows a registry-based study.

24 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

The U.S. Food and Drug Administration, in a complaint filed by the U.S. Department of Justice, is seeking a permanent injunction against the dietary supplement manufacturer James G. Cole, Inc., its president, James G. Cole, and its general manager, Julie D. Graves, following the company's repeated distribution of unapproved drugs and adulterated dietary supplements in violation of the Federal Food, Drug, and Cosmetic Act.

23 Oct 2013

Orygen To Manufacture Epirus' Remicade Biosimilar In Brazil

...

22 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

22 Oct 2013

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, is delighted to announce its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

22 Oct 2013

Clinical trials will help to develop treatment and follow-up of COPD patients

Three major clinical trials will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis in Norway.

22 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

Arthritis Society launches campaign to urge Canadians to speak up, "Share The Pain"

The Arthritis Society today launched a nationwide campaign to urge Canadians to speak up and "Share The Pain" they experience in living with arthritis. The Society is aiming to change the conversation about arthritis and trigger a candid, national discussion on the reality of a disease that affects millions of Canadians of every age.

21 Oct 2013

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEA® (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO).

21 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Good news: Knowing risk early, women can take action to prevent osteoporosis

On World Osteoporosis Day, October 20, the International Osteoporosis Foundation (IOF) is calling for women to take action now to protect their bone health. Broken bones due to osteoporosis often result in pain, immobility and loss of quality of life as well as early death.

17 Oct 2013

NIH funding helps develop chronic-pain network to accelerate research, treatments

What do migraine, irritable bowel syndrome, fibromyalgia and rheumatoid arthritis have in common? All involve chronic pain.

17 Oct 2013

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

DPP-4 inhibitors may reduce risk of autoimmune diseases

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Patients with severe rheumatoid arthritis more likely to have heart problems

Autoimmune link to schizophrenia

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

Orygen To Manufacture Epirus' Remicade Biosimilar In Brazil

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Novozymes Biopharma partners with Almac to provide combined service for drug development

Clinical trials will help to develop treatment and follow-up of COPD patients

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Arthritis Society launches campaign to urge Canadians to speak up, "Share The Pain"

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Good news: Knowing risk early, women can take action to prevent osteoporosis

NIH funding helps develop chronic-pain network to accelerate research, treatments

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in